- Home
- YCBD vs REVB Comparison
YCBD vs REVB Comparison
Compare YCBD & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YCBD
- REVB
- Stock Information
- Founded
- YCBD 2015
- REVB 2020
- Country
- YCBD United States
- REVB United States
- Employees
- YCBD N/A
- REVB N/A
- Industry
- YCBD Biotechnology: Pharmaceutical Preparations
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- YCBD Health Care
- REVB Health Care
- Exchange
- YCBD Nasdaq
- REVB Nasdaq
- Market Cap
- YCBD 1.8M
- REVB 1.4M
- IPO Year
- YCBD N/A
- REVB N/A
- Fundamental
- Price
- YCBD $0.40
- REVB $0.34
- Analyst Decision
- YCBD
- REVB
- Analyst Count
- YCBD 0
- REVB 0
- Target Price
- YCBD N/A
- REVB N/A
- AVG Volume (30 Days)
- YCBD 743.5K
- REVB 1.7M
- Earning Date
- YCBD 02-11-2025
- REVB 11-08-2024
- Dividend Yield
- YCBD N/A
- REVB N/A
- EPS Growth
- YCBD N/A
- REVB N/A
- EPS
- YCBD N/A
- REVB N/A
- Revenue
- YCBD $20,636,546.00
- REVB N/A
- Revenue This Year
- YCBD N/A
- REVB N/A
- Revenue Next Year
- YCBD $9.38
- REVB N/A
- P/E Ratio
- YCBD N/A
- REVB N/A
- Revenue Growth
- YCBD N/A
- REVB N/A
- 52 Week Low
- YCBD $0.31
- REVB $0.32
- 52 Week High
- YCBD $1.73
- REVB $25.26
- Technical
- Relative Strength Index (RSI)
- YCBD 42.55
- REVB 27.29
- Support Level
- YCBD $0.31
- REVB $0.32
- Resistance Level
- YCBD $0.58
- REVB $0.47
- Average True Range (ATR)
- YCBD 0.06
- REVB 0.08
- MACD
- YCBD -0.01
- REVB -0.02
- Stochastic Oscillator
- YCBD 32.34
- REVB 3.40
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD and hempMD. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD bath bombs, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).